Inventor · disambiguated record
Michael D. Bartberger
Also filed as: BARTBERGER MICHAEL · BARTBERGER MICHAEL D · BARTBERGER MICHAEL DAVID
24 granted patents·14 pending applications·178 citations·filing 2005–2025
95Inventor score
Files withAMGEN INC21ALTEROME THERAPEUTICS INC5CALIFORNIA INST OF TECHN4HENRIKSSON MARTIN21200 PHARMA LLC1
Top patents by PatentIndex Score
38 records- 0197US11096939B2KRAS G12C inhibitors and methods of using the sameAMGEN INC·Filed 2019·Granted Aug 24, 2021·24 cites·30 claims
- 0297US11045484B2KRAS G12C inhibitors and methods of using the sameAMGEN INC·Filed 2019·Granted Jun 29, 2021·24 cites·34 claims
- 0397US10988485B2KRAS G12C inhibitors and methods of using the sameAMGEN INC·Filed 2019·Granted Apr 27, 2021·27 cites·51 claims
- 0491US11999730B1AKT1 modulatorsALTEROME THERAPEUTICS INC·Filed 2023·Granted Jun 4, 2024·2 cites·29 claims
- 0591US7253196B2Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1BIOVITRUM AB·Filed 2005·Granted Aug 7, 2007·19 cites·15 claims
- 0688US9593129B2Piperidinone derivatives as MDM2 inhibitors for the treatment of cancerAMGEN INC·Filed 2016·Granted Mar 14, 2017·5 cites·18 claims
- 0788US9296736B2Piperidinone derivatives as MDM2 inhibitors for the treatment of cancerAMGEN INC·Filed 2014·Granted Mar 29, 2016·7 cites·13 claims
- 0888US7807700B2Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1AMGEN INC·Filed 2007·Granted Oct 5, 2010·12 cites·16 claims
- 0988US7666888B2Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1AMGEN INC·Filed 2007·Granted Feb 23, 2010·22 cites·14 claims
- 1087US2024300892A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2023·Application pending·0 cites
- 1186US9376425B2Heterocyclic compounds as MDM2 inhibitors for the treatment of cancerAMGEN INC·Filed 2012·Granted Jun 28, 2016·12 cites·37 claims
- 1286US7872009B2Beta-Secretase modulators and methods of useAMGEN INC·Filed 2006·Granted Jan 18, 2011·11 cites·8 claims
- 1380US2022169611A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2022·Application pending·0 cites
- 1479US11332459B2Benzimidazole derivatives and their usesTEIJIN PHARMA LTD·Filed 2018·Granted May 17, 2022·2 cites·16 claims
- 1579US2025092040A1Akt1 modulatorsALTEROME THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1677US12209087B2AKT1 modulatorsALTEROME THERAPEUTICS INC·Filed 2024·Granted Jan 28, 2025·0 cites·20 claims
- 1777US7745484B2Beta-secretase modulators and methods of useAMGEN INC·Filed 2006·Granted Jun 29, 2010·2 cites·15 claims
- 1877US2025346610A1SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORSALTEROME THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1974US8541592B2Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1HENRIKSSON MARTIN·Filed 2006·Granted Sep 24, 2013·3 cites·11 claims
- 2074US2021179560A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2020·Application pending·0 cites
- 2173US12466842B2Substituted pyrido [4,3-d]pyrimidines as KRAS modulatorsALTEROME THERAPEUTICS INC·Filed 2025·Granted Nov 11, 2025·0 cites·30 claims
- 2272US8686011B2Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1HENRIKSSON MARTIN·Filed 2011·Granted Apr 1, 2014·3 cites·5 claims
- 2372US7973047B2Beta-Secretase modulators and methods of useAMGEN INC·Filed 2010·Granted Jul 5, 2011·2 cites·21 claims
- 2470US7838676B2Beta-secretase modulators and methods of useAMGEN INC·Filed 2006·Granted Nov 23, 2010·1 cites·11 claims
- 2567US2019062276A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2018·Application pending·0 cites
- 2665US2014011796A1Piperidinone derivatives as mdm2 inhibitors for the treatment of cancerAMGEN INC·Filed 2013·Application pending·0 cites
- 2764US2017144971A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2017·Application pending·0 cites
- 2854US2025136582A1Select kras g12c inhibitors and uses thereof1200 PHARMA LLC·Filed 2022·Application pending·0 cites
- 2949US12486280B2CDK inhibitors and uses thereofCALIFORNIA INST OF TECHN·Filed 2019·Granted Dec 2, 2025·0 cites·23 claims
- 3048US2011082107A1Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1AMGEN INC·Filed 2010·Application pending·0 cites
- 3147US12428416B2ERK inhibitors and uses thereofCALIFORNIA INST OF TECHN·Filed 2019·Granted Sep 30, 2025·0 cites·20 claims
- 3246US2016002185A1Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancerAMGEN INC·Filed 2014·Application pending·0 cites
- 3346US2023116602A1Mcl1 inhibitors and uses thereofCALIFORNIA INST OF TECHN·Filed 2020·Application pending·0 cites
- 3444US2022227738A1Kras g12c inhibitors and uses thereofCALIFORNIA INST OF TECHN·Filed 2020·Application pending·0 cites
- 3543US11407721B2CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancerAMGEN INC·Filed 2018·Granted Aug 9, 2022·0 cites·46 claims
- 3643US8163766B2Beta-secretase modulators and methods of useZHONG WENGE·Filed 2010·Granted Apr 24, 2012·0 cites·10 claims
- 3740US2014155415A1Benzodioxepine and benzodioxine compounds that interact with glucokinase regulatory protein for the treatment of diabetesBARTBERGER MICHAEL DAVID·Filed 2012·Application pending·0 cites
- 3830US8431563B2Compounds that interact with glucokinase regulatory protein for the treatment of diabetesASHTON KATE·Filed 2011·Granted Apr 30, 2013·0 cites·34 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →